Cast21 Revenue and Competitors
Estimated Revenue & Valuation
- Cast21's estimated annual revenue is currently $5M per year.
- Cast21's estimated revenue per employee is $251,000
Employee Data
- Cast21 has 20 Employees.
Cast21's People
Name | Title | Email/Phone |
---|---|---|
1 | CTO | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | VP Sales | Reveal Email/Phone |
4 | Territory Sales Manager | Reveal Email/Phone |
5 | Lead R&D Engineer | Reveal Email/Phone |
Cast21 Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $63.5M | 253 | 6% | N/A | N/A |
#2 | $13.6M | 54 | 10% | N/A | N/A |
#3 | $9.8M | 39 | 0% | N/A | N/A |
#4 | $1.5M | 6 | -60% | N/A | N/A |
#5 | $21.1M | 84 | -3% | N/A | N/A |
#6 | $38.4M | 153 | -1% | N/A | N/A |
#7 | $114.2M | 455 | 4% | N/A | N/A |
#8 | $45.9M | 183 | -6% | N/A | N/A |
#9 | $12450M | 38512 | 1% | $1.7B | N/A |
#10 | $4.3M | 17 | -60% | N/A | N/A |
What Is Cast21?
Cast21 is a medical device company that creates innovative healthcare solutions, inspiring change in the way the world heals. Our first product offers a waterproof alternative to casting or bracing for the treatment of bone fractures or joint injuries. This alternative improves the quality of life of patients through its breathable and lightweight design. Doctors benefit from a streamlined application and removal process that does not require any scanning or sawing equipment, heat, water, or electricity. We are registered and listed with the Food and Drug Administration (FDA), and our product is available at select clinics nationwide. #DemandTheBest
keywords:N/AN/A
Total Funding
20
Number of Employees
$5M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.7M | 20 | 11% | N/A |
#2 | $7.5M | 20 | -20% | N/A |
#3 | $2M | 20 | N/A | N/A |
#4 | $2M | 20 | N/A | N/A |
#5 | $3.8M | 20 | -5% | N/A |